Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

FDG-PET Scanning Shows Distributed Changes in Cortical Activity Associated with Visual Hallucinations in Eye Disease

Author(s): Lütfü Hanoglu, Sultan Yildiz, Tansel Cakir, Taha Hanoglu and Burak Yulug*

Volume 19, Issue 1, 2019

Page: [84 - 89] Pages: 6

DOI: 10.2174/1871530318666180830112709

Price: $65

conference banner
Abstract

Background and Objective: Charles Bonnet Syndrome (CBS) has been defined as complex visual hallucinations (CVH) due to visual loss. The underlying mechanism of CBS is not clear and the underlying pathophysiology of the visual hallucinations in CBS patients and pure visually impaired patients is still not clear.

Methods: In our study, we have scanned three patients with eye disease and CBS (VH+) and three patients with eye disease without CBS (VH-) using FDG-PET.

Results: Our results showed underactivity in the pons and overactivity in primary right left visual cortex and inferior parietal cortex in VH- patients and underactivity in left Broca, left inf frontal primary visual cortex and anterior and posterior cingulate cortex in VH+ patients relative to the normative 18FFDG PET data that was taken from the database consisting of 50 age-matched healthy adults without neuropsychiatric disorders.

Conclusion: From this distributed pattern of activity changes, we conclude that the generation of visual hallucination in CBS is associated with bottom-up and top-down mechanism rather than the generally accepted visual deafferentation-related hyperexcitability theory.

Keywords: Visual hallucination, charles bonnet syndrome, 18F-FDG PET scanning, visual deafferentation theory, glaucoma, age-related macular degeneration, diabetic retinopathy.

« Previous Next »
Graphical Abstract

[1]
Russell, G.; Harper, R.; Allen, H.; Baldwin, R.; Burns, A. Cognitive impairment and Charles Bonnet syndrome: A prospective study. Int. J. Geriatr. Psychiatry, 2018, 33(1), 39-46.
[2]
Bou, K.R.; Richa, S. Psychiatric, psychological comorbidities of typical and atypical Charles Bonnet syndrome. Encephale, 2011, 37(6), 473-480.
[3]
Podoll, K.; Osterheider, M.; Noth, J. The Charles Bonnet syndrome. Fortschr. Neurol. Psychiatr., 1989, 57(2), 43-60.
[4]
Gold, K.; Rabins, P.V. Isolated visual hallucinations and the Charles Bonnet syndrome: A review of the literature and presentation of six cases. Compr. Psychiatry, 1989, 30(1), 90-98.
[5]
Menon, G.J.; Rahman, I.; Menon, S.J.; Dutton, G.N. Complex visual hallucinations in the visually impaired: The Charles Bonnet Syndrome. Surv. Ophthalmol., 2003, 48(1), 58-72.
[6]
Kazui, H.; Ishii, R.; Yoshida, T.; Ikezawa, K.; Takaya, M.; Tokunaga, H.; Tanaka, T.; Takeda, M. Neuroimaging studies in patients with Charles Bonnet Syndrome. Psychogeriatrics, 2009, 9(2), 77-84.
[7]
Adachi, N.; Watanabe, T.; Matsuda, H.; Onuma, T. Hyperperfusion in the lateral temporal cortex, the striatum and the thalamus during complex visual hallucinations: Single photon emission computed tomography findings in patients with Charles Bonnet syndrome. Psychiatry Clin. Neurosci., 2000, 54(2), 157-162.
[8]
Jang, J.W.; Youn, Y.C.; Seok, J.W.; Ha, S.Y.; Shin, H.W.; Ahan, S.W.; Park, K.Y.; Kwon, O.S. Hypermetabolism in the left thalamus and right inferior temporal area on Positron Emission Tomography-Statistical Parametric Mapping (PET-SPM) in a patient with Charles Bonnet syndrome resolving after treatment with valproic acid. J. Clin. Neurosci., 2011, 18(8), 1130-1132.
[9]
Graham, G.; Dean, J.; Mosimann, U.P.; Colbourn, C.; Dudley, R.; Clarke, M.; Collerton, D. Specific attentional impairments and complex visual hallucinations in eye disease. Int. J. Geriatr. Psychiatry, 2011, 26, 263-267.
[10]
Shine, J.M.; O’Callaghan, C.; Halliday, G.M.; Lewis, S.J. Tricks of the mind: Visual hallucinations as disorders of attention. Prog. Neurobiol., 2014, 116, 58-65.
[11]
Onofrj, M.; Taylor, J.P.; Monaco, D.; Franciotti, R.; Anzellotti, B.L.; Onofrj, V.; Thomas, A. Visual hallucinations in pd and lewy body dementias: Old and new hypotheses. Behav. Neurol., 2013, 27, 479-493.
[12]
Choi, M.Y.; Lee, D.S.; Hwang, J.M.; Choi, D.G.; Lee, K.M.; Park, K.H.; Yu, Y.S. Characteristics of glucose metabolism in the visual cortex of amblyopes using positron-emission tomography and statistical parametric mapping. J. Pediatr. Ophthalmol. Strabismus, 2002, 39(1), 11-19.
[13]
Holroyd, S.; Rabins, P.V.; Finkelstein, D.; Nicholson, M.C.; Chase, G.A.; Wisniewski, S.C. Visual hallucinations in patients with macular degeneration. Am. J. Psychiatry, 1992, 149(12), 1701-1706.
[14]
Papapetropoulos, S.; Katzen, H.; Schrag, A.; Singer, C.; Scanlon, B.K.; Nation, D. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease. BMC Neurol., 2008, 8, 21.
[15]
Akdemir, Ü.Ö.; Tokçaer, A.B.; Karakuş, A.; Kapucu, L.Ö. Brain 18FFDG PET imaging in the differential diagnosis of parkinsonism. Clin. Nucl. Med., 2014, 39, 220-226.
[16]
Cogan, D.G. Visual hallucinations as release phenomena. Graefes Arch. Clin. Exp. Ophthalmol., 1973, 188, 139-150.
[17]
Ffytche, D.H. The hodology of hallucinations. Cortex, 2008, 44, 1067-1083.

Rights & Permissions Print Cite
Article Metrics
32
3
Wayfinder Image
World Diabetes Day
© 2024 Bentham Science Publishers | Privacy Policy